David Schaffer - Oct 20, 2021 Form 4 Insider Report for 4D Molecular Therapeutics Inc. (FDMT)

Role
Director
Signature
/s/ August J. Moretti, Attorney-in-Fact for David Schaffer
Stock symbol
FDMT
Transactions as of
Oct 20, 2021
Transactions value $
-$1,137,819
Form type
4
Date filed
10/22/2021, 09:42 PM
Previous filing
Oct 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Sale -$359K -11.6K -1.23% $31.02 926K Oct 20, 2021 Direct F1, F2
transaction FDMT Common Stock Sale -$720K -22.8K -2.46% $31.56 903K Oct 21, 2021 Direct F1, F3
transaction FDMT Common Stock Sale -$58.9K -1.9K -0.21% $31.00 901K Oct 22, 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $30.27 to $32.07,inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The transaction was executed in multiple trades in prices ranging from $30.70 to $32.39, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 The transaction was executed in multiple trades in prices ranging from $30.76 to $31.66, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.